Shares of Prime Medicine, Inc. (NYSEARCA:PRME – Get Rating) were down 4.6% during mid-day trading on Friday . The stock traded as low as $14.26 and last traded at $14.43. Approximately 41,304 shares were traded during trading, a decline of 77% from the average daily volume of 181,909 shares. The stock had previously closed at […]
Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) has been given a consensus recommendation of “Hold” by the sixteen brokerages that are currently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and four have issued a buy recommendation on the company. The […]
Research analysts at Stifel Nicolaus assumed coverage on shares of Prime Medicine (NYSEARCA:PRME – Get Rating) in a note issued to investors on Monday, The Fly reports. The brokerage set a “buy” rating on the stock. Separately, Morgan Stanley reduced their price objective on Prime Medicine from $23.00 to $21.00 and set an “equal weight” […]
Editas Medicine (NASDAQ:EDIT – Get Rating) had its price target reduced by investment analysts at Chardan Capital from $60.00 to $43.00 in a report issued on Wednesday, The Fly reports. The brokerage presently has a “buy” rating on the stock. Chardan Capital’s price objective would suggest a potential upside of 268.47% from the stock’s previous […]